Evidence map›Paper›PMID 42683267›Full record

ReviewFrontiers in immunology2026

Lymphocyte activation gene 3 in autoimmune disease: from molecular mechanisms to clinical applications.

Lishuang Guo, Lu Pan, Congcong Liu, Sirui Yang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lishuang Guo *Department of Pediatric Rheumatology, Immunology & Allergy, Children's Medical Center, The First Hospital of Jilin University, Changchun, China.
Lu Pan *Department of Pediatric Rheumatology, Immunology & Allergy, Children's Medical Center, The First Hospital of Jilin University, Changchun, China.
Congcong LiuDepartment of Pediatric Rheumatology, Immunology & Allergy, Children's Medical Center, The First Hospital of Jilin University, Changchun, China.
Sirui YangDepartment of Pediatric Rheumatology, Immunology & Allergy, Children's Medical Center, The First Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymphocyte activation gene 3 (LAG3) has become an important immune checkpoint receptor, which plays a crucial role in regulating the immune response. The immunoregulatory function of LAG3 is achieved through complex receptor-ligand interactions, structure-function relationships, and unique signaling pathways. The role of LAG3 in cancers has been widely explored, and drugs targeting LAG3 are constantly emerging, demonstrating promising application prospects. In autoimmune diseases, downregulation of LAG3 leads to the breakdown of immune tolerance and excessive immune activation. In this review, we begin with the mechanisms by which LAG3 exerts its immunosuppressive function and its role in the immune system, focusing on the role of LAG3 in autoimmune diseases and recent research progress.

Indexed as

Antigens, CDAutoimmune DiseasesAnimalsHumansImmune ToleranceLymphocyte ActivationLymphocyte Activation Gene 3 ProteinSignal TransductionAntigens, CDLag3 protein, humanLymphocyte Activation Gene 3 Proteinautoimmune diseaseinhibitory immune receptorsLAG3mechanismmolecular mechanism

Identifiers

PMID42683267
PMCPMC13531452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.